Project Details
Description
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
| Status | Finished |
|---|---|
| Effective start/end date | 4/30/16 → 12/31/20 |
Funding
- MIRATI THERAPEUTICS, INC.